524606 BERLDRG

Beryl Drugs Share Price

₹33.00 +0.25 (0.76%)

21 Nov, 2024 19:50

SIP TrendupStart SIP in BERLDRG

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume0

Investment Returns

  • Over 1 Month -11.41%
  • Over 3 Month + 2.68%
  • Over 6 Month -10.47%
  • Over 1 Year + 60.19%
SIP Lightning

Smart Investing Starts Here Start SIP with Beryl Drugs for Steady Growth!

Invest Now

Beryl Drugs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Beryl Drugs Financials

Beryl Drugs Technicals

EMA & SMA

Current Price
₹33.00
+ 0.25 (0.76%)
pointer
  • stock-down_img
  • Bullish Moving Average 0
  • stock-up_img
  • Bearish Moving Average 16
  • 20 Day
  • ₹36.03
  • 50 Day
  • ₹36.50
  • 100 Day
  • ₹35.58
  • 200 Day
  • ₹33.18

Resistance and Support

32.92 Pivot Speed
  • R3 37.77
  • R2 36.36
  • R1 34.33
  • S1 30.89
  • S2 29.48
  • S3 27.45

What's your outlook on Beryl Drugs?

You can only vote for once

Beryl Drugs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-13 Quarterly Results
2024-08-09 Quarterly Results
2024-05-30 Audited Results
2024-04-20 Others
2024-02-12 Quarterly Results

Beryl Drugs F&O

Beryl Drugs Shareholding Pattern

No data available.

About Beryl Drugs

  • NSE Symbol
  • BERLDRG
  • BSE Symbol
  • 524606
  • ISIN
  • INE415H01017

Similar Stocks to Beryl Drugs

Beryl Drugs FAQs

Beryl Drugs share price is ₹33 As on 21 November, 2024 | 19:36

The Market Cap of Beryl Drugs is ₹16.7 Cr As on 21 November, 2024 | 19:36

The P/E ratio of Beryl Drugs is 49.4 As on 21 November, 2024 | 19:36

The PB ratio of Beryl Drugs is 1.9 As on 21 November, 2024 | 19:36

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23